CClinicalTrials.gg
CompletedNCT01699269TeDi-C2Updated Jul 8, 2014

Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging

An interventional study of peritumoral glial cell infiltration in High Grade Brain Tumor, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI), in order to evaluate the peripheral white matter infiltration of high grade brain tumors. Organized architecture is destroyed once brain tumor cells are infiltrating surrounding tissue. The infiltrated tissue is then isotropic (or less anisotropic). DT-MRI can assess anisotropy after datasets post treatment. Primary outcome is to find if a correlation exists between GA (generalized anisotropy) and the infiltration percentage of stereotactic peritumoral biopsies.

Read the detailed description

Patients with high grade brain tumor undergo a usual brain tumor MRI protocol as well as a 20 or 60 directions DT-MRI sequence upon patient collaboration. Images are acquired using a 3 Tesla MRI scanner (GE MR750 Discovery).

The usual brain tumor MRI protocol contains the following sequences: 3DT1, Axial T2, Flair, T2 EG, diffusion (b0-b1000), 3DT1CE.

They will then undergo stereotactic tumor biopsies with Leksell frame mounted.

Biopsy targets will be surgically planned. The coordinates of this first biopsy will be recorded for later coregistration with DT-MRI datasets.

Histopathologic analysis of the biopsies will be done using usual procedure. various immunologic markers such as MAP2, Ki67 will be used on the first biopsy sample in order to estimate the percentage of infiltration (ratio of tumor cells number over total cells number).

Analysis of DT-MRI datasets will be done using home-made software for high order tensor resolution and GA estimation at the exact coordinates of the biopsy sites.

Finally a statistical analysis (Pearson or Spearman) will be done to correlate GA and the infiltration percentage.

02

Conditions studied

  • High Grade Brain Tumor

Browse trials for

Keywords

  • High grade brain tumor
  • Glioma
  • Glioblastoma Multiform
  • Brain Cancer
  • Diffusion-Weighted Magnetic Resonance Imaging
  • High order diffusion tensor
  • Imaging guided biopsy
  • Histopathologic evaluation
  • Infiltration percentage
03

In context

Brain Neoplasms

1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's enrollment of 10 is below the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 841 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with high grade brain tumor
  • Age greater than 18 yo and under 85 yo
  • Signed informed consent from patient

Exclusion criteria

Exclusion Criteria:

  • -Any person with pacemaker, metal implant, claustrophobia, or any other contraindication for MR examination
  • Severe renal failure
  • Brain tumor biopsy contraindication
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
10 participants (actual)

Study arms

  • Other
    brain tumor

    Other: peritumoral glial cell infiltration

Interventions

  • Otherperitumoral glial cell infiltration
06

What researchers measure

Primary outcomes

  1. DTI-MRI

    Time frame: at J0

Secondary outcomes

  1. Biopsy

    Time frame: at J+1

  2. count cell

    Time frame: at J+10

  3. datas co-registration

    Time frame: at J+20

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01699269
Lead sponsor
University Hospital, Clermont-Ferrand
Responsible party
Sponsor
First posted
Oct 3, 2012
Start date
Apr 2012
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Jul 8, 2014

Study contacts

Betty JEAN
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion